Navigation Links
Cardinal Health Reports Fiscal 2008 Results, Provides Fiscal 2009 Outlook
Date:8/7/2008

Company Exploring Spin-Off of Clinical And Medical Products Businesses

- Annual revenue increases 5 percent to $91 billion - GAAP diluted earnings per share from continuing operations increase 76

percent to $3.64 and 11 percent to $3.80 on a non-GAAP basis - Fourth quarter revenue increases 3 percent to $23 billion, GAAP diluted earnings per share from continuing operations increase 51 percent to $0.92

and 9 percent to $0.97 on a non-GAAP basis

- Reserve taken in connection with settlement discussions with Drug

Enforcement Administration - Fiscal 2009 non-GAAP earnings per share expected to be $3.80 to $3.95 as

company makes significant investments in R&D, IT

DUBLIN, Ohio, Aug. 7 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today reported an increase in fiscal 2008 revenue of 5 percent to $91 billion and a 76 percent increase in GAAP earnings per share (EPS) to $3.64. On a non-GAAP basis, EPS grew 11 percent to $3.80(1) for the year.

As the company had forecasted, the medical supply chain segment improved profit in the second half of the year, driven by double-digit growth in its core U.S. medical distribution business. Significant steps were taken in the pharmaceutical distribution business during the year to accelerate a recovery, which the company expects in the second half of fiscal 2009.

Results during the quarter and year continued to highlight growth within the company's medical technology segments. Combined revenue for the Clinical Technologies and Services, and Medical Products and Technologies segments grew by 24 percent to $5.6 billion and profit increased 36 percent to nearly $800 million for the year.

Cardinal Health also announced that its board of directors has supported a management recommendation to actively explore a potentties related to the integration of acquired businesses; and conditions in the pharmaceutical market and general economic and market conditions. This news release reflects management's views as of Aug. 7, 2008. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.

CARDINAL HEALTH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)

Fourth Quarter

(in millions, except per Common Share

amounts) 2008 2007 % Change

Revenue $22,925.6 $22,262.8 3 %

Cost of products sold 21,456.2 20,905.4 3 %

Gross margin 1,469.4 1,357.4 8 %

Selling, general and administrative

expenses 901.3 819.3 10 %

Impairment charges and other (10.0) (0.6) N.M.

Special items:

Restructuring charges 10.9 11.7 N.M.

Acquisition integration charges 25.1 87.5 N.M.

Litigation and other (1.1) 19.0 N.M.

Operating earnings 543.2 420.5 29 %

Interest expense and other 47.4 19.1 148 %

Earnings before income taxes and

discontinued operations 495.8 401.4 24 %

Provision for income taxes 165.6 163.7 1 %

Earnings from continuing operations 330.2 237.7 39 %

Earnings / (loss) from discontinued

operations (net of tax expense

of $2.8 and $448.3 for the fourth

quarter of fiscal 2008 and 2007,

respectively) (3.6) 664.5 N.M.

Net earnings $326.6 $902.2 (64)%

Basic earnings / (loss) per Common Share:

Continuing operations $0.93 $0.63 48 %

Discontinued operations (0.01) 1.76 N.M.

Net basic earnings per Common Share $0.92 $2.39 (62)%

Diluted earnings / (loss) per Common Share:

Continuing operations $0.92 $0.61 51 %

Discontinued operations (0.01) 1.72 N.M.

Net diluted earnings per Common Share $0.91 $2.33 (61)%

Weighted average number of Common

Shares outstanding:

Basic 355.5 378.2

Diluted 359.8 387.4

CARDINAL HEALTH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)

Fiscal Year

(in millions, except per Common Share

amounts) 2008 2007 % Change

Revenue $91,091.4 $86,852.0 5 %

Cost of products sold 85,457.3 81,606.7 5 %

Gross margin 5,634.1 5,245.3 7 %

Selling, general and administrative

expenses 3,414.8 3,082.3 11 %

Impairment charges and other (32.0) 17.3 N.M.

Special items:

Restructuring charges 65.7 40.1 N.M.

Acquisition integration charges 44.9 101.5 N.M.

Litigation and other 12.0 630.4 N.M.

Operating earnings 2,128.7 1,373.7 55 %

Interest expense and other 171.4 121.4 41 %

Earnings before income taxes and

discontinued operations 1,957.3 1,252.3 56 %

Provision for income taxes 632.8 412.6 53 %

Earnings from continuing operations 1,324.5 839.7 58 %

Earnings / (loss) from discontinued

operations (net of tax expense

of $31.9 and $20.4 for fiscal 2008

and 2007, respectively) (15.3) 1,091.4 N.M.

Net earnings $1,309.2 $1,931.1 (32)%

Basic earnings / (loss) per Common Share:

Continuing operations $3.70 $2.13 74 %

Discontinued operations (0.04) 2.76 N.M.

Net basic earnings per Common Share $3.66 $4.89 (25)%

Diluted earnings / (loss) per Common Share:

Continuing operations $3.64 $2.07 76 %

Discontinued operations (0.04) 2.70 N.M.

Net diluted earnings per Common Share $3.60 $4.77 (25)%

Weighted average number of Common

Shares outstanding:

Basic 358.2 394.9

Diluted 364.0 404.7

CARDINAL HEALTH, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

June 30, June 30,

(in millions) 2008 2007

Assets

Cash and equivalents $1,291.3 $1,308.8

Short-term investments available for sale - 132.0

Trade receivables, net 5,006.9 4,714.4

Current portion of net investment in

sales-type leases 383.7 354.8

Inventories 6,768.8 7,383.2

Prepaid expenses and other 593.1 651.3

Assets held for sale 140.4 -

Total current assets 14,184.2 14,544.5

Property and equipment, net 1,737.2 1,647.0

Net investment in sales-type leases,

less current portion 916.8 820.7

Goodwill and other intangibles, net 6,225.9 5,860.9

Other assets 384.1 280.7

Total assets $23,448.2 $23,153.8

Liabilities and Shareholders' Equity

Current portion of long-term

obligations and other short-term borrowings $159.0 $16.0

Accounts payable 8,311.8 9,162.2

Other accrued liabilities 1,881.1 2,247.3

Liabilities from businesses held for

sale and discontinued operations 15.4 34.2

Total current liabilities 10,367.3 11,459.7

Long-term obligations, less current

portion and other short-term borrowings 3,687.4 3,457.3

Deferred income taxes and other liabilities 1,637.4 859.9

Total shareholders' equity 7,756.1 7,376.9

Total liabilities and shareholders' equity $23,448.2 $23,153.8

CARDINAL HEALTH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Fourth Quarter Fiscal Year

(in millions) 2008 2007 2008 2007

Cash Flows From Operating

Activities:

Net earnings $326.6 $902.2 $1,309.2 $1,931.1

(Earnings) / loss from

discontinued operations 3.6 (664.5) 15.3 (1,091.4)

Earnings from continuing

operations 330.2 237.7 1,324.5 839.7

Adjustments to reconcile

earnings from continuing

operations to net cash

provided by / (used in)

operating activities:

Depreciation and

amortization 96.3 85.0 381.3 322.1

Asset impairments and other (10.6) 1.2 (31.4) 19.2

Purchased in-process

research and development 18.0 84.5 18.0 84.5

Equity compensation 35.6 28.8 122.3 138.1

Provision for deferred

income taxes 26.9 11.7 26.9 11.7

Provision for bad debts 3.8 7.0 26.1 24.0

Change in operating assets

and liabilities, net of

effects from acquisitions:

(Increase) / decrease in

trade receivables (17.8) 36.6 (312.7) (783.1)

Decrease in inventories 499.3 205.9 613.1 217.4

Increase in net investment

in sales-type leases (41.1) (53.8) (124.9) (130.8)

Increase / (decrease) in

accounts payable (595.9) (268.6) (813.1) 224.4

Increase / (decrease) in

other accrued liabilities

and operating items, net (98.0) (667.6) 329.0 35.8

Net cash provided by /

(used in) operating

activities - continuing

operations 246.7 (291.6) 1,559.1 1,003.0

Net cash provided by /

(used in) operating

activities - discontinued

operations (4.4) 104.9 (47.0) 220.1

Net cash provided by / (used

in) operating activities 242.3 (186.7) 1,512.1 1,223.1

Cash Flows From Investing

Activities:

Acquisition of subsidiaries,

net of divestitures and

cash acquired (475.9) (1,480.9) (514.9) (1,629.8)

Proceeds from sale of

property and equipment 22.4 5.6 32.6 9.2

Additions to property and

equipment (124.5) (114.3) (376.1) (357.4)

Sale of investment

securities available for

sale, net - 168.0 132.0 366.5

Net cash used in investing

activities - continuing

operations (578.0) (1,421.6) (726.4) (1,611.5)

Net cash provided by

investing activities -

discontinued operations - 3,228.9 - 3,148.7

Net cash provided by / (used

in) investing activities (578.0) 1,807.3 (726.4) 1,537.2

Cash Flows From Financing

Activities:

Net change in commercial

paper and short-term

borrowings (202.7) (293.3) (0.5) (38.9)

Reduction of long-term

obligations (4.6) (51.1) (21.5) (784.0)

Proceeds from long-term

obligations, net of

issuance costs 302.5 601.7 303.5 1,453.4

Proceeds from issuance of

Common Shares 18.6 233.7 227.9 552.6

Tax benefits from exercises

of stock options 26.8 1.1 42.1 29.9

Dividends on Common Shares (42.6) (34.9) (173.1) (144.4)

Purchase of Common Shares in

treasury - (1,636.7) (1,181.6) (3,662.0)

Net cash provided by /

(used in) financing

activities - continuing

operations 98.0 (1,179.5) (803.2) (2,593.4)

Net cash provided by /

(used in) financing

activities - discontinued

operations - 1.2 - (45.4)

Net cash provided by /

(used) in financing

activities 98.0 (1,178.3) (803.2) (2,638.8)

Net increase / (decrease) in

cash and equivalents (237.7) 442.3 (17.5) 121.5

Cash and equivalents at

beginning of period 1,529.0 866.5 1,308.8 1,187.3

Cash and equivalents at end

of period $1,291.3 $1,308.8 $1,291.3 $1,308.8

CARDINAL HEALTH, INC. AND SUBSIDIARIES

BUSINESS ANALYSIS

TOTAL COMPANY

Non-GAAP

Fourth Quarter Fourth Quarter

(in millions) 2008 2007 2008 2007

Revenue

Amount $22,926 $22,263

Growth Rate 3 % 5 %

Operating Earnings

Amount $543 $421 $568 $538

Growth Rate 29 % (14)% 6 % 3 %

Earnings from Continuing Operations

Amount $330 $238 $348 $345

Growth Rate 39 % (22)% 1 % 5 %

Non-GAAP

Fiscal Year Fiscal Year

(in millions) 2008 2007 2008 2007

Revenue

Amount $91,091 $86,852

Growth Rate 5 % 9 %

Operating Earnings

Amount $2,129 $1,374 $2,219 $2,163

Growth Rate 55 % (26)% 3 % 12 %

Earnings from Continuing Operations

Amount $1,325 $840 $1,385 $1,384

Growth Rate 58 % (28)% - 13 %

Refer to the GAAP / Non-GAAP Reconciliation for definitions and

calculations supporting the non-GAAP balances.

CARDINAL HEALTH, INC. AND SUBSIDIARIES

SEGMENT BUSINESS ANALYSIS

HEALTHCARE SUPPLY CHAIN SERVICES CLINICAL AND MEDICAL PRODUCTS

Fourth Quarter Fourth Quarter

(in millions) 2008 2007 (in millions) 2008 2007

PHARMACEUTICAL CLINICAL TECHNOLOGIES AND SERVICES

Revenue Revenue

Amount $19,819 $19,556 Amount $780 $756

Growth Rate 1 % 4 % Growth Rate 3 % 17 %

Mix 85 % 86 % Mix 3 % 3 %

Segment Profit Segment Profit

Amount $258 $303 Amount $156 $144

Growth Rate (15)% (3)% Growth Rate 8 % 50 %

Mix 44 % 52 % Mix 26 % 24 %

Segment Profit Segment Profit

Margin 1.30 % 1.55 % Margin 20.01 % 19.06 %

MEDICAL MEDICAL PRODUCTS AND TECHNOLOGIES

Revenue Revenue

Amount $2,082 $1,929 Amount $727 $500

Growth Rate 8 % 5 % Growth Rate 46 % 14 %

Mix 9 % 9 % Mix 3 % 2 %

Segment Profit Segment Profit

Amount $81 $83 Amount $95 $58

Growth Rate (3)% (2)% Growth Rate 63 % 27 %

Mix 14 % 14 % Mix 16 % 10 %

Segment Profit Segment Profit

Margin 3.89 % 4.32 % Margin 13.01 % 11.60 %

Refer to definitions for an explanation of calculations.

CARDINAL HEALTH, INC. AND SUBSIDIARIES

SEGMENT BUSINESS ANALYSIS

HEALTHCARE SUPPLY CHAIN SERVICES CLINICAL AND MEDICAL PRODUCTS

Fiscal Year Fiscal Year

(in millions) 2008 2007 (in millions) 2008 2007

PHARMACEUTICAL CLINICAL TECHNOLOGIES AND SERVICES

Revenue Revenue

Amount $79,284 $76,573 Amount $2,890 $2,687

Growth Rate 4 % 9 % Growth Rate 8 % 11 %

Mix 85 % 86 % Mix 3 % 3 %

Segment Profit Segment Profit

Amount $1,122 $1,300 Amount $497 $386

Growth Rate (14)% 14 % Growth Rate 29 % 20 %

Mix 50 % 59 % Mix 22 % 18 %

Segment Profit Segment Profit

Margin 1.41 % 1.70 % Margin 17.18 % 14.35 %

MEDICAL MEDICAL PRODUCTS AND TECHNOLOGIES

Revenue Revenue

Amount $8,084 $7,514 Amount $2,696 $1,836

Growth Rate 8 % 4 % Growth Rate 47 % 12 %

Mix 9 % 9 % Mix 3 % 2 %

Segment Profit Segment Profit

Amount $303 $318 Amount $300 $198

Growth Rate (5)% 1 % Growth Rate 52 % 20 %

Mix 14 % 14 % Mix 14 % 9 %

Segment Profit Segment Profit

Margin 3.75 % 4.23 % Margin 11.14 % 10.76 %

Refer to the definitions for an explanation of how the Company calculates

segment profit.

CARDINAL HEALTH, INC. AND SUBSIDIARIES

SCHEDULE OF NOTABLE ITEMS

Fourth Quarter Fiscal Year

(in millions, except per Common

Share amounts) 2008 2007 2008 2007

Special Items

Restructuring charges $(10.9) $(11.7) $(65.7) $(40.1)

Acquisition integration charges (25.1) (87.5) (44.9) (101.5)

Litigation and other 1.1 (19.0) (12.0) (630.4)

Total special items (34.9) (118.2) (122.6) (772.0)

Tax benefit 13.1 10.4 44.9 243.1

Special items, net of tax $(21.8) $(107.8) $(77.7) $(528.9)

Decrease to diluted EPS from

continuing operations $(0.06) $(0.28) $(0.21) $(1.31)

Impairment Charges and Other

Impairment charges and other $10.0 $0.6 $32.0 $(17.3)

Tax benefit / (expense) (6.0) (0.2) (14.4) 1.6

Impairment charges and other, net

of tax $4.0 $0.4 $17.6ial separation of the company's primary operating and reporting segments, which could involve a tax-free spin-off of the clinical and medical products businesses as a separate, publicly traded company. Cardinal Health plans to announce its decision within approximately 60 to 90 days.

"For two years, we have been taking steps to sharpen our focus on health care supply chain services and clinical and medical products, culminating with our announcement in July to operate these businesses in two distinct segments that reflect the unique characteristics and requirements of each," said R. Kerry Clark, chairman and chief executive officer of Cardinal Health. "As we now consider a spin-off of our clinical and medical products businesses, our goal is simple: to have two thriving businesses, delivering maximum value to customers and shareholders over the long term."

Fiscal 2008 Results

Consolidated revenue for fiscal 2008 grew 5 percent to $91 billion and GAAP earnings from continuing operations rose 58 percent to $1.3 billion. Diluted earnings per share from continuing operations grew 76 percent to $3.64, or 11 percent to $3.80 on a non-GAAP basis. Earnings in the prior year were negatively affected by a $600 million expense to resolve securities litigation.

During the fourth quarter, ended June 30, consolidated revenue increased 3 percent to $23 billion, and earnings from continuing operations increased 39 percent to $330 million. Earnings in the fourth quarter of the prior year were dampened by merger-related charges from the company's acquisition of VIASYS Healthcare. Excluding the impact of merger charges and other items, non-GAAP earnings from continuing operations increased 1 percent to $348 million(2), or 9 percent to $0.97 on a diluted per-share basis.

"Overall, fourth quarter results were in line with our expectations," Clark said. "We continued to demonstrate to customers the value of our clinically differentiated medical technolo $(15.7)

Increase / (decrease) to diluted

EPS from continuing operations $0.01 - $0.05 $(0.04)

Weighted Average Number of Diluted

Shares Outstanding 359.8 387.4 364.0 404.7

CARDINAL HEALTH, INC. AND SUBSIDIARIES

ASSET MANAGEMENT ANALYSIS

Fourth Quarter Fiscal Year

2008 2007 2008 2007

Receivable Days 20.9 20.5

Days Inventory on Hand 25 28

Debt to Total Capital 33 % 32 %

Net Debt to Capital 25 % 22 %

Return on Equity 17.3% 47.3% 17.8% 23.5%

Non-GAAP Return on Equity 18.4% 17.3% 19.0% 16.9%

Return on Invested Capital 6.90% 18.43% 7.01% 9.38%

Non-GAAP Return on Invested Capital 8.00% 7.00% 8.06% 7.14%

Effective Tax Rate from Continuing

Operations 33.4% 40.8% 32.3% 33.0%

Non-GAAP Effective Tax Rate from

Continuing Operations 33.7% 33.5% 32.6% 32.4%

Refer to the GAAP / Non-GAAP Reconciliation for non-GAAP calculations.

CARDINAL HEALTH, INC. AND SUBSIDIARIES

GAAP / NON-GAAP RECONCILIATION

Fourth Quarter 2008

Impairment

(in millions, except per Common Special Charges

Share amounts) GAAP Items and Other Non-GAAP

Operating Earnings

Amount $543 $35 ($10) $568

Growth Rate 29 % 6 %

Provision for Income Taxes $166 $13 ($6) $173

Earnings from Continuing Operations

Amount $330 $22 ($4) $348

Growth Rate 39 % 1 %

Diluted EPS from Continuing Operations

Amount $0.92 $0.06 ($0.01) $0.97

Growth Rate 51 % 9%

Fiscal Year 2008

Impairment

(in millions, except per Common Special Charges

Share amounts) GAAP Items and Other Non-GAAP

Operating Earnings

Amount $2,129 $123 ($32) $2,219

Growth Rate 55 % 3 %

Provision for Income Taxes $633 $45 ($14) $663

Earnings from Continuing Operations

Amount $1,324 $78 ($18) $1,385

Growth Rate 58 % -

Diluted EPS from Continuing Operations

Amount $3.64 $0.21 ($0.05) $3.80

Growth Rate 76 % 11 %

Fourth Quarter 2007

Impairment

Special Charges

GAAP Items and Other Non-GAAP

Operating Earnings

Amount $421 $118 ($1) $538

Growth Rate (14)% 3 %

Provision for Income Taxes $164 $10 - $174

Earnings from Continuing Operations

Amount $238 $108 - $345

Growth Rate (22)% 5 %

Diluted EPS from Continuing Operations

Amount $0.61 $0.28 - $0.89

Growth Rate (15)% 14%

Fiscal Year 2007

Impairment

Special Charges

GAAP Items and Other Non-GAAP

Operating Earnings

Amount $1,374 $772 $17 $2,163

Growth Rate (26)% 12 %

Provision for Income Taxes $413 $243 $2 $657

Earnings from Continuing Operations

Amount $840 $529 $16 $1,384

Growth Rate (28)% 13 %

Diluted EPS from Continuing Operations

Amount $2.07 $1.31 $0.04 $3.42

Growth Rate (24)% 20%

The sum of the components may not equal the total due to rounding

CARDINAL HEALTH, INC. AND SUBSIDIARIES

GAAP / NON-GAAP RECONCILIATION

Fourth Quarter Fiscal Year

(in millions) 2008 2007 2008 2007

GAAP Return on Equity 17.3% 47.3% 17.8% 23.5%

Non-GAAP Return on Equity

Net earnings $326.6 $902.2 $1,309.2 $1,931.1

Special items, net of tax, in

continuing operations 21.8 107.8 77.7 528.9

Special items, net of tax, in

discontinued operations - - - 4.4

(Gain)/loss on sale of PTS,

net of tax, in discontinued

operations - (679.5) 7.6 (1,072.4)

Adjusted net earnings $348.4 $330.5 $1,394.5 $1,392.0

Annualized $1,393.6 $1,322.0 $1,394.5 $1,392.0

Divided by average

shareholders' equity(1) $7,574.7 $7,623.2 $7,340.5 $8,213.2

Non-GAAP return on equity 18.4% 17.3% 19.0% 16.9%

Fourth Quarter Fiscal Year

(in millions) 2008 2007 2008 2007

GAAP Return on Invested Capital 6.90% 18.43% 7.01% 9.38%

Non-GAAP Return on Invested

Capital

Net earnings $326.6 $902.2 $1,309.2 $1,931.1

Special items, net of tax, in

continuing operations 21.8 107.8 77.7 528.9

Special items, net of tax, in

discontinued operations - - - 4.4

Interest expense and other,

net of tax 30.4 12.2 109.7 77.7

(Gain)/loss on sale of PTS,

net of tax, in discontinued

operations - (679.5) 7.6 (1,072.4)

Adjusted net earnings $378.8 $342.7 $1,504.2 $1,469.7

Annualized $1,515.2 $1,370.8 $1,504.2 $1,469.7

Divided by average total

invested capital(2) $18,940.1 $19,583.8 $18,665.9 $20,580.7

Non-GAAP return on invested

capital 8.00% 7.00% 8.06% 7.14%

(1) The average shareholders' equity shown above is calculated using

the average of the prior and current quarters except for fiscal

year which is calculated as the average of shareholders' equity

at the end of the prior years' fourth quarter plus each of the

current year quarters.

(2) Total invested capital is calculated as the sum of the current

portion of long-term obligations and other short-term borrowings,

long-term obligations, current portion of long-term obligations and

other short-term borrowings in discontinued operations, long-term

obligations in discontinued operations, total shareholders' equity

and unrecorded goodwill. The average total invested capital is

calculated using the average of total invested capital at the end of

the prior and current quarters except for year-to-date which is

calculated as the average of the prior years' fourth quarter plus

each of the current year quarters. Unrecorded goodwill is

$7.5 billion for all periods presented. Current portion of long-term

obligations and other short-term borrowings in discontinued

operations, and long-term obligations in discontinued operations were

$59.2 million, $46.6 million, $41.3 million and $12.3 million at June

30, 2006, September 30, 2006, December 31, 2006 and March 31, 2007,

respectively.

CARDINAL HEALTH, INC. AND SUBSIDIARIES

GAAP / NON-GAAP RECONCILIATION

Fiscal Year

(in millions) 2008 2007

Revenue

Clinical Technologies and Services $2,890 $2,687

Medical Products and Technologies 2,696 1,836

Combined Revenue $5,586 $4,523

Combined Growth Rate 24 %

Segment Profit

Clinical Technologies and Services $497 $386

Medical Products and Technologies 300 198

Combined Profit $797 $584

Combined Growth Rate 36 %

Fourth Quarter

(in millions) 2008 2007

Clinical Technologies and Services

revenue growth 3%

Clinical Technologies and Services

revenue $779.8 $755.8

Less: Pharmacy Services business

unit revenue (194.8) (218.7)

Clinical Technologies and Services

revenue excluding Pharmacy Services

business unit revenue $585.0 $537.1

Clinical Technologies and Services

revenue growth excluding Pharmacy

Services business unit revenue 9%

CARDINAL HEALTH, INC. AND SUBSIDIARIES

GAAP / NON-GAAP RECONCILIATION

Fourth Quarter Fiscal Year

(in millions) 2008 2007 2008 2007

GAAP Effective Tax Rate from

Continuing Operations 33.4% 40.8% 32.3% 33.0%

Non-GAAP Effective Tax Rate from

Continuing Operations

Earnings before income taxes and

discontinued operations $495.8 $401.4 $1,957.3 $1,252.3

Special items 34.9 118.2 122.6 772.0

Adjusted earnings before

income taxes and discontinued

operations $530.7 $519.6 $2,079.9 $2,024.3

Provision for income taxes $165.6 $163.7 $632.8 $412.6

Special items tax benefit 13.1 10.4 44.9 243.1

Adjusted provision for income

taxes $178.7 $174.1 $677.7 $655.7

Non-GAAP effective tax rate from

continuing operations 33.7% 33.5% 32.6% 32.4%

Fourth Quarter

2008 2007

Debt to Total Capital 33% 32%

Net Debt to Capital

Current portion of long-term

obligations and other short-

term borrowings $159.0 $16.0

Long-term obligations, less

current portion and other

short-term borrowings 3,687.4 3,457.3

Debt $3,846.4 $3,473.3

Cash and equivalents (1,291.3) (1,308.8)

Short-term investments available

for sale - (132.0)

Net debt $2,555.1 $2,032.5

Total shareholders' equity $7,756.1 $7,376.9

Capital $10,311.2 $9,409.4

Net debt to capital 25% 22%

Forward-Looking Non-GAAP Financial Measures

The Company presents non-GAAP earnings from continuing operations and

non-GAAP effective tax rate from continuing operations (and presentations

derived from these financial measures) on a forward-looking basis. The

most directly comparable forward-looking GAAP measures are earnings from

continuing operations and effective tax rate from continuing operations.

The Company is unable to provide a quantitative reconciliation of these

forward-looking non-GAAP measures to the most comparable forward-looking

GAAP measures because the Company cannot reliably forecast special items

and impairment charges and other, which are difficult to predict and

estimate and are primarily dependent on future events. Please note that

the unavailable reconciling items could significantly impact the

Company's future financial results.

CARDINAL HEALTH, INC. AND SUBSIDIARIES

DEFINITIONS

GAAP

Debt: long-term obligations plus short-term borrowings Debt to Total Capital: debt divided by (debt plus total shareholders' equity)

Diluted EPS from Continuing Operations: earnings from continuing operations divided by diluted weighted average shares outstanding

Effective Tax Rate from Continuing Operations: provision for income taxes divided by earnings before income taxes and discontinued operations

Operating Cash Flow: net cash provided by / (used in) operating activities from continuing operations

Segment Profit: segment revenue minus (segment cost of products sold and segment selling, general and administrative expenses)

Segment Profit Margin: segment profit divided by segment revenue

Segment Profit Mix: segment profit divided by total segment profit for all segments

Return on Equity: annualized net earnings divided by average shareholders' equity

Return on Invested Capital: annualized net earnings divided by (average total shareholders' equity plus debt plus unrecorded goodwill)

Revenue Mix: segment revenue divided by total segment revenue for all segments

NON-GAAP

Net Debt to Capital: net debt divided by (net debt plus total shareholders' equity)

Net Debt: debt minus (cash and equivalents and short-term investments available for sale)

Non-GAAP Diluted EPS from Continuing Operations: non-GAAP earnings from continuing operations divided by diluted weighted average shares outstanding

Non-GAAP Diluted EPS from Continuing Operations Growth Rate: (current period non-GAAP diluted EPS from continuing operations minus prior period non- GAAP diluted EPS from continuing operations) divided by prior period non-GAAP diluted EPS from continuing operations

Non-GAAP Earnings from Continuing Operations: earnings from continuing operations excluding special items and impairment charges and other, both net of tax

Non-GAAP Earnings from Continuing Operations Growth Rate: (current period non-GAAP earnings from continuing operations minus prior period non-GAAP earnings from continuing operations) divided by prior period non-GAAP earnings from continuing operations

Non-GAAP Effective Tax Rate from Continuing Operations: (provision for income taxes adjusted for special items) divided by (earnings before income taxes and discontinued operations adjusted for special items)

Non-GAAP Operating Earnings: operating earnings excluding special items and impairment charges and other

Non-GAAP Operating Earnings Growth Rate: (current period non-GAAP operating earnings minus prior period non-GAAP operating earnings) divided by prior period non-GAAP operating earnings

Non-GAAP Return on Equity: (annualized current period net earnings plus special items minus special items tax benefit) divided by average shareholders' equity (1)

Non-GAAP Return on Invested Capital: (annualized net earnings plus special items minus special items tax benefit plus interest expense and other) divided by (average total shareholders' equity plus debt plus unrecorded goodwill) (1)

(1) For the three months ended June 30, 2007, the numerator in calculating

this non-GAAP financial measure also excludes the $679.5 million gain,

net of tax, on the sale of PTS recorded in discontinued operations in

the fourth quarter of fiscal 2007. For the fiscal year ended June

30, 2008 and 2007 the numerator in calculating this non-GAAP financial

measure also excludes the respective $7.6 million and $(1,072.4)

million (gain) / loss, net of tax, on the sale of PTS recorded in

discontinued operations.

gies, where we delivered a year of very strong growth on the top and bottom lines. We also made steady progress throughout the year in our medical supply chain segment and, in particular, are very pleased with the results in our hospital, lab and ambulatory care distribution business.

"In our pharmaceutical supply chain segment, we believe we are on the right path to resolve the license suspensions that have kept us from distributing controlled substances from three of our 24 distribution centers. This will be a critical step in our efforts to drive improvements in the business. And while we won't speculate on the ultimate outcome, we are in constructive settlement discussions with the DEA and have recorded a reserve of $23.5 million in connection with those discussions. We have made good progress in enhancing our controls and are eager to return to full service levels for our customers."

Q4 and FY08 Summary

Q4 FY08 Q4 FY07 Y/Y FY08 Y/Y

Revenue $23 billion $22 billion 3% $91 billion 5%

Operating Earnings $543 million $421 million 29% $2.1 billion 55%

Non-GAAP Operating

Earnings(3) $568 million $538 million 6% $2.2 billion 3%

Earnings from

Continuing Operations $330 million $238 million 39% $1.3 billion 58%

Non-GAAP Earnings from

Continuing Operations $348 million $345 million 1% $1.4 billion -

Diluted EPS from

Continuing Operations $0.92 $0.61 51% $3.64 76%

Non-GAAP Diluted EPS from

Continuing Operations $0.97 $0.89 9% $3.80 11%

Fourth-quarter and full-year segment results

Revenue for the Healthcare Supply Chain Services - Pharmaceutical segment increased 1 percent to $19.8 billion for the quarter with sales to bulk customers increasing by 9 percent. Sales to non-bulk customers decreased by 5 percent, primarily due to the transfer of volume from non-bulk to bulk sales by a large customer and the loss of business associated with controlled substance anti-diversion efforts. As expected, segment profit declined 15 percent to $258 million, driven by previously disclosed customer re-pricings, and direct-store-door customer losses, including the impact of anti-diversion efforts. The profit decline was partially offset by branded pharmaceutical price increases and greater profit from distribution service agreement fees.

For the year, segment revenue reached $79.3 billion, an increase of 4 percent, and segment profit was $1.1 billion, declining 14 percent from last year.

Fourth-quarter revenue for the Healthcare Supply Chain Services - Medical segment increased 8 percent to $2.1 billion, driven by increased sales to existing hospital, laboratory and ambulatory customers. Segment profit for the quarter decreased 3 percent to $81 million, but included a previously disclosed corporate allocation adjustment that reduced profit by 6 percentage points. Strong, double-digit profit growth from the distribution of medical and surgical products in the U.S. partially offset the decline in segment profit from other factors. As the company had forecasted, segment profit grew in the second half of fiscal 2008 compared to the second half of fiscal 2007.

Full-year revenue for the segment increased 8 percent to $8.1 billion, and full-year profit declined 5 percent to $303 million.

The Medical Products and Technologies segment reported a 46 percent increase in fourth-quarter revenue to $727 million, primarily driven by the acquisitions of VIASYS Healthcare and Enturia, but also organic growth in the core infection prevention and respiratory businesses. Segment profit increased 63 percent to $95 million and included a favorable impact of 38 percentage points from acquisitions. During the quarter, the company discovered it had failed to recognize profit on a portion of intercompany sales from fiscal 2006 to 2008. As a result, approximately $16 million was recorded as income for the fourth quarter that pertained to prior periods. The VIASYS integration continues to be ahead of schedule to achieve planned synergy goals by 2010.

For the full year, segment revenue increased 47 percent to $2.7 billion and segment profit grew 52 percent to $300 million, including 39 percentage points from acquisitions.

Compared to a record quarter in the prior year, fourth-quarter revenue for the Clinical Technologies and Services segment increased 3 percent to $780 million, driven by continued strength in installations of medication dispensing products. Excluding Pharmacy Services, revenue increased 9 percent. Segment profit for the quarter exceeded company expectations, rising 8 percent to $156 million driven by favorable product mix and a positive impact from foreign exchange.

Full-year revenue for the segment increased 8 percent to $2.9 billion and segment profit increased 29 percent to $497 million.

Additional fourth-quarter and recent highlights include:

-- Reaching a definitive agreement to sell Tecomet, a maker of orthopedic implants, to Charlesbank Capital Partners and Tecomet management, with plans to close within 60 days;

-- Reaching a definitive agreement to acquire Borschow Medical and Hospital Supplies, Inc., the largest distributor of pharmaceutical products and medical supplies in Puerto Rico;

-- Completing the acquisition of assets of privately held Enturia, Inc., the manufacturer of infection prevention products sold under the ChloraPrep(R) brand name;

-- Introducing the Pyxis(R) DuoStation, a new system that leverages the company's industry-leading dispensing technologies to enable clinicians access to a patient's medications and medical supplies from one system;

-- Launching four new offerings for retail independent pharmacies at the company's 19th annual Retail Business Conference, including a private-label brand of durable medical equipment, front-of-store management system, automated calling technology and automated pill counting systems;

-- A three-year agreement to serve as primary supply chain partner for Prime Therapeutics, one of the nation's largest pharmacy benefit managers, which serves approximately 14.6 million members nationwide;

-- Contracts with Premier for Alaris(R) infusion systems, Presource(R) custom procedure packs, Convertors(R) surgical drapes and gowns, third-party instrument repair, respiratory equipment, Pyxis(R) medication and supply automation products, and ChloraPrep(R) brand chlorhexidine gluconate (CHG) skin prep products.

Outlook

"In fiscal 2009, we plan to make incremental investments of up to $100 million to strengthen R&D in the clinical and medical products business and improve information technology in the supply chain services business," Clark said. "These investments will affect our earnings growth rates in fiscal 2009, but are important, foundational moves that we believe will accelerate future growth in both segments."

For fiscal 2009, the company expects revenue growth of 6 to 7 percent. Non-GAAP diluted EPS from continuing operations is expected to be in a range of $3.80 to $3.95 based on investments the company plans to make in new product development and information technology, and previously disclosed challenges in the pharmaceutical distribution business that are expected to continue through the first half of the fiscal year, coupled with a particularly unfavorable comparison in the first quarter due to strong branded price inflation in the prior year period.

As a result, non-GAAP EPS in the first quarter is expected to be around $0.70. The company forecasts EPS to return to more normal levels in the second quarter, with overall company results stronger in the second half of the year.

Fiscal 2009 Financial Goals

Revenue Growth 6-7%

Non-GAAP EPS $3.80 - $3.95

Segment Revenue Growth Profit Growth

Healthcare Supply Chain Services >6% Flat to (5%)

Clinical and Medical Products >10% >20%

(Please reference the company's slide presentation for corporate and segment assumptions related to fiscal 2009 guidance, including that the potential separation of the clinical and medical products businesses does not occur during fiscal 2009. The presentation is posted on the Investor page at http://www.cardinalhealth.com).

The Healthcare Supply Chain Services segment is expected to return to profitable growth in the second half of the year. The first half of the year will continue to be affected by the company's ability to resolve license suspensions to distribute controlled substances from three of its pharmaceutical distribution centers, previously disclosed repricing of some major contracts and volatility in the Nuclear Pharmacy Services business leading to the launch of generic sestimibi.

The Clinical and Medical Products segment is expected to continue on a strong growth trajectory based on momentum in current product lines and approximately 50 new product introductions or enhancements planned during the next 18 months.

Conference Call

Cardinal Health will host a conference call and webcast at 8:30 a.m. EDT to discuss the results. To access the call and corresponding slide presentation, go to the Investor page at http://www.cardinalhealth.com. The conference call may also be accessed by calling 617-213-4850, conference passcode 97674427. An audio replay will be available until 11 p.m. EDT on Aug. 9 at 617-801-6888, passcode 28260453. A transcript and audio replay will also be available at http://www.cardinalhealth.com.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market leading technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems, MedMined(TM) infection surveillance services and the CareFusion(TM) patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at http://www.cardinalhealth.com.

(1) Non-GAAP diluted EPS from continuing operations: Non-GAAP earnings

from continuing operations divided by diluted weighted average shares

outstanding.

(2) Non-GAAP earnings from continuing operations: Earnings from

continuing operations excluding special items and impairment charges

and other, both net of tax.

(3) Non-GAAP operating earnings: Operating earnings excluding special

items and impairment charges and other.

A reconciliation of the differences between these non-GAAP financial measures and their most directly comparable GAAP financial measures is provided in the attached tables and at http://www.cardinalhealth.com.

This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: uncertainties regarding the decision to explore the separation of the company's clinical and medical products businesses and regarding the impacts of such decision if the separation is accomplished; competitive pressures in Cardinal Health's various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; uncertainties relating to timing of generic and branded pharmaceutical introductions and the frequency or rate of branded pharmaceutical price appreciation or generic pharmaceutical price deflation; changes in the distribution patterns or reimbursement rates for health-care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal or administrative proceedings; future actions of regulatory bodies or government authorities relating to Cardinal Health's manufacturing or sale of products and other costs or claims that could arise from its manufacturing, compounding or repackaging operations or from its other services; difficulties, delays or additional costs in implementing the restructuring program announced on July 8, 2008; the costs, difficulties and uncertain
'/>"/>

SOURCE Cardinal Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Health Declares Regular Quarterly Dividend
2. Cardinal Health Expands Leader(R) Offering To Help Independent Pharmacies Strengthen Patient Relationships, Solidify Role As Local Health Care Experts
3. Cardinal Health Formalizes Consolidation of Businesses Into Two Primary Operating and Reporting Segments
4. Cardinal Health Increases Quarterly Dividend by 17 Percent
5. Cardinal Health Reports Third Quarter Results
6. Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives
7. Cardinal Health to Announce Third-Quarter Results on May 1
8. Cardinal Health, ClearCount Medical Solutions Sign Primary Distribution Agreement for RFID-Enabled Sponge Counting, Detection System
9. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
10. Cardinal Health Names Former Acting Deputy U.S. Attorney General Craig S. Morford to Chief Compliance Officer Post
11. Cardinal Health Names Michael C. Kaufmann to Lead Pharmaceutical Segment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: